Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine utilized primarily as adjunctive therapy for seizures. Unlike 1,4-benzodiazepines, it possesses a unique 1,5-structure that may result in a more favorable therapeutic index regarding sedation and respiratory depression, though dependency and tolerance remain significant risks.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS). Off-label use includes refractory epilepsy and anxiety disorders.
## Adult Dosing
* **Initial Dose:** 10 mg/day.
* **Titration:** Increase to 20 mg/day after one week. May increase to a maximum of 40 mg/day if tolerated.
* **Administration:** Doses >20 mg/day should be divided into twice-daily administration.
## Pediatric Dosing
* **Age:** Patients ≥2 years old.
* **Weight-based dosing (LGS):**
* **≤30 kg:** Start 5 mg/day; titrate to 10 mg/day after one week, then 20 mg/day if needed.
* **>30 kg:** Start 10 mg/day; titrate to 20 mg/day after one week, then 40 mg/day if needed.
* **Administration:** Doses >5 mg/day (for ≤30 kg) or >20 mg/day (for >30 kg) should be divided twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50%; titrate slowly. Use caution in severe impairment.
* **Renal Impairment:** No specific data; use with caution.
* **Geriatric:** Initiate at the lower end of the dosing spectrum (5 mg/day) and monitor for cognitive/motor impairment.
* **CYP2C19 Poor Metabolizers:** Exposure to the active metabolite (N-desmethylclobazam) is significantly increased. Start at 50% of the recommended dose.
## Contraindications
* Hypersensitivity to clobazam or any components.
* Myasthenia gravis (may exacerbate neuromuscular weakness).
## Adverse Effects
* **Common:** Somnolence, lethargy, pyrexia, constipation, drooling, cough, and ataxia.
* **Serious:** Severe dermatological reactions (Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), suicidal ideation, dependence/withdrawal (if abruptly stopped), and respiratory depression (especially if combined with opioids).
## Key Drug Interactions
* **Opioids:** Concomitant use significantly increases the risk of profound sedation, respiratory depression, coma, and death.
* **CYP2C19 Inhibitors (e.g., Fluconazole, Fluvoxamine):** May markedly increase clobazam metabolite levels.
* **CNS Depressants:** Enhanced depressant effects with alcohol, barbiturates, and other benzodiazepines.
* **Hormonal Contraceptives:** May decrease the effectiveness of estrogen-containing oral contraceptives.
## Monitoring
* **Dermatological:** Monitor for new rashes, blisters, or mucosal lesions (stop immediately if SJS/TEN is suspected).
* **Behavioral:** Monitor for worsening depression, mood changes, or suicidal thoughts.
* **Neurological:** Monitor for excessive sedation or motor impairment.
* **Tapering:** Abrupt withdrawal may precipitate status epilepticus; taper gradually over weeks.
## Clinical Pearls
* **Metabolism:** Active metabolite (N-desmethylclobazam) has a long half-life, which contributes to its clinical duration but prolongs the washout period.
* **Dosing protocol:** Always confirm if your facility employs specific titration schedules (e.g., for transitioning patients from other anticonvulsants).
* **Dosing flexibility:** Tablets may be crushed and mixed with applesauce; the oral suspension is also available for patients with swallowing difficulties.
***
**Disclaimer:** This information is for educational purposes only. Always consult the latest FDA-approved prescribing information, local institutional protocols, and clinical pharmacist databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.
